Series A first close · Biotech
mbiomics raises €13m in first Series A close
MIG Capital leads financing for microbiome therapeutics.
mbiomics announced a €13 million first Series A close on March 23, 2023, led by MIG Capital AG. High-Tech Gründerfonds, Bayern Kapital and private seed investors also participated.
The Munich biotechnology company will expand its laboratories and research team, develop partnerships and build its microbial therapeutics platform. Its approach uses precision microbiome analysis to design bacterial communities for pharmaceutical development.
Use of funds
Build the microbiome therapeutics platform
Expand laboratory facilities and R&D teams
Develop strategic partnerships
Funding history
Series A first close · This round€13M